Tyra Biosciences, Inc. (TYRA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Tyra Biosciences, Inc. is a clinical-stage biotechnology company developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology. The company operates as a single reportable segment focused on oncology and genetically defined conditions. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(28.1) million | $(56.2) million | $(36.9) million |
| Operating Expenses | $31.5 million | $63.3 million | $45.9 million |
| Interest & Other Income | $3.4 million | $7.1 million | $9.0 million |
| Cash & Marketable Securities | $296.3 million (as of June 30, 2025) | ||
| Net Cash Used in Operating Activities | $(49.1) million (YTD 2025) |
Note: All figures in millions unless otherwise noted. The company has no product revenue and relies on interest income and capital reserves.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2025, increased by $19.4 million compared to the same period in 2024, driven by higher operating expenses.
- R&D Expense Growth: Research and development expenses rose by $14.1 million year-over-year (YTD). This was primarily due to $9.6 million in increased clinical start-up and enrollment costs for the BEACH301, SURF302, and SURF431 trials, alongside higher personnel costs.
- Decline in Interest Income: Interest and other income decreased by $1.9 million YTD due to lower interest rates and reduced cash balances.
- Investing Cash Flow: Net cash provided by investing activities turned positive ($52.9 million) compared to a significant outflow in 2024, driven by maturities of marketable securities exceeding new purchases.
Outlook, Management Commentary, and Risks
- Clinical Progress:
- Dabogratinib (TYRA-300): First patient dosed in June 2025 for the SURF302 trial (non-muscle invasive bladder cancer). The BEACH301 trial (pediatric achondroplasia) is expected to dose its first child in Q3 2025.
- TYRA-430: Patient dosing commenced in April 2025 for hepatocellular carcinoma.
- Liquidity: Management believes current cash, cash equivalents, and marketable securities ($296.3 million) are sufficient to fund operations through at least 2027.
- Capital Resources: The company entered a new "at-the-market" (ATM) sales agreement with TD Securities in May 2025 for up to $150 million, replacing a terminated agreement with Virtu Americas. No shares have been sold under the new agreement as of June 30, 2025.
- Risks: The company has never generated revenue and expects to incur significant losses until regulatory approval is obtained. Future capital needs may require equity or debt financing, which could dilute shareholders. Clinical trial outcomes and regulatory approvals remain uncertain.
- Subsequent Event: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025, modifying tax laws. The company does not currently anticipate a material change to its effective tax rate due to its full valuation allowance.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $296.3 million cash position against the accelerating burn rate driven by multiple Phase 1/2 trials.
- ATM Agreement Utilization: Monitor if and when the company utilizes the new $150 million ATM facility with TD Securities to raise capital.
- Clinical Milestones: Track the enrollment and safety data for the BEACH301 (achondroplasia) and SURF302 (bladder cancer) trials, with initial data expected in H1 2026.
- Stock-Based Compensation: Review the impact of $12.8 million in stock-based compensation (YTD 2025) on future cash burn and dilution.
- Regulatory Path: Assess the timeline for regulatory filings based on the completion of ongoing Phase 1/2 studies.